Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsGraft vs Leukemia EffectTreatment OutcomeBone Marrow TransplantationMyeloablative AgonistsTissue DonorsBusulfanRemission InductionVidarabineRecurrenceGraft vs Tumor EffectGraft SurvivalSurvival RateHistocompatibility TestingDisease-Free SurvivalLymphocyte TransfusionRetrospective StudiesImmunosuppressive AgentsLeukemia, Myeloid, AcuteMultiple MyelomaSurvival AnalysisLeukemiaCombined Modality TherapySiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCord Blood Stem Cell TransplantationCytomegalovirus InfectionsHematopoietic Stem CellsMinor Histocompatibility AntigensSalvage TherapyLiver TransplantationWhole-Body IrradiationLymphocyte DepletionAntilymphocyte SerumMyelodysplastic SyndromesNeoplasm, ResidualVirus ActivationPrecursor Cell Lymphoblastic Leukemia-LymphomaHistocompatibilityMelphalanTime FactorsChimerismAntineoplastic Combined Chemotherapy ProtocolsHepatic Veno-Occlusive DiseaseCyclophosphamideMesenchymal Stem Cell TransplantationCytomegalovirusHematopoietic Stem Cell MobilizationT-LymphocytesFollow-Up StudiesAcute DiseasePrimary MyelofibrosisKidney TransplantationCell TransplantationPrognosisAnemia, AplasticHLA AntigensEmbryonic Stem CellsHematologic DiseasesLeukemia, Myeloid, Accelerated PhaseAntigens, CD34Antibodies, NeoplasmAntineoplastic AgentsCytarabineImmunosuppressionTransplantation ImmunologyRoseolovirus InfectionsBenzamidesAdult Stem CellsLeukemia, MyeloidLymphoproliferative DisordersImmunocompromised HostFusion Proteins, bcr-ablHodgkin DiseaseReceptors, Purinergic P2X5PyrimidinesCell SurvivalGraft RejectionNuclear FamilyLymphoma, Non-HodgkinPiperazinesGanciclovirGranulocyte Colony-Stimulating FactorInfectionCyclosporineHeart TransplantationFatal OutcomeImmunotherapy, AdoptiveCell DifferentiationOpportunistic InfectionsLiving Donors